Cognision today unveiled Cognision360(TM), a groundbreaking web-based platform that consolidates multiple neurobiomarker data streams into a single, standardized system--addressing one of the ...

Partnership launched under MTEA to evaluate the potential of Vect-Horus technology to deliver siRNAs into the CNSAssessment of BBB shuttle–siRNA ...

More than a half-billion dollars worth of fentanyl was seized in California over the past five years as part of expanded drug enforcement efforts at the southern border, Gov. Gavin Newsom announced ...

Qelbree-led growth, Sage acquisition synergies, and <4x forward P/S support ~25% upside into 2026. Click for more on SUPN ...

A five-year-old patient dosed with RGX-111 has developed a brain tumour four years after being dosed with the gene therapy.

Shares of Regenxbio plunged after the Food and Drug Administration placed clinical holds on two drug development programs after a five-year-old participant in one study developed an intraventricular ...

TRPML1 is a promising target1 for Parkinson’s disease treatments and identifying translational biomarkers will help confirm target engagement ...

REGENXBIO Inc. (Nasdaq: RGNX) today announced that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its ...

Despite new methodologies and flexible regulatory pathways, CNS biopharmaceuticals still face significant safety assessment ...

Law defines DUI as driving “under the influence of or affected by intoxicating liquor, cannabis, or any drug,” or a ...

Despite warnings, potentially inappropriate CNS-active medications are commonly prescribed to older adults — especially those with cognitive impairment — highlighting missed opportunities for safer ...

Questionable prescribing of CNS-active drugs persists ...